Global Policy Forum Chair, Dan Ollendorf (United States), 2020-22

Dr. Dan Ollendorf is Director of Value Measurement and Global Health Initiatives at the Center for the Evaluation of Value and Risk in Health (CEVR) at Tufts University. His research interests include expanding the use of health technology assessment in developing economies, as well as refinement of value assessment tools in the US and other developed settings. Prior to joining CEVR, he was Chief Scientific Officer for the Institute for Clinical and Economic Review (ICER) for over 10 years, where he was responsible for the conduct of assessments of the clinical effectiveness and economic value of high impact health care technologies as well as coordination of the broader HTA process. His 30 years of experience also include work in the hospital, informatics, insurance, and consulting sectors. Dr. Ollendorf holds a PhD in clinical epidemiology from the University of Amsterdam, a MPH from Boston University, and a BA from the University of Rochester. He currently serves as a non-resident Fellow at the Center for Global Development, is a member of a joint task force on HTA deliberative processes co-sponsored by HTAi and the International Society of Pharmacoeconomics and Outcomes Research (ISPOR), and is also a member of ISPOR’s working group on HTA in pluralistic health systems.

Editor in Chief, International Journal of Technology Assessment in Health Care, Wendy Babidge (Australia)

Wendy Babidge is General Manager of Research, Audit and Academic Surgery at the Royal Australasian College of Surgeons. This includes the Australian Safety and Efficacy Register of New Interventional Procedures-Surgical (ASERNIP- S) Health Technology Assessment group, which was established in 1998.

Wendy has an Honours Degree in Biotechnology, a PhD from the University of Adelaide and a Graduate Diploma in Business. She is a Graduate of the Australian Institute of Company Directors and an Associate Professor of the University of Adelaide.

Wendy is a past Chair of the International Network of Agencies for Health Technology Assessment (INAHTA) Board and Editor-in-Chief HTAi’s journal, the International Journal of Technology Assessment in Health Care.

INAHTA Board Chair, Sophie Werkö (Sweden)

Dr Werkö has an MSc in Business Administration and a PhD from the University of Stockholm. She has a longstanding engagement with HTA and started in HTA as Project Director at The Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU). In 2012 she was appointed Manager of International Relations at SBU, responsible for coordinating SBU’s international work and she is also leading the work on Patient Involvement at SBU.

 

As Chair of the International Network of Agencies for Health Technology Assessment (INAHTA), she has an important role of leading the global network of publicly funded HTA agencies. She has participated in the work of the European network for Health Technology Assessment (EUnetHTA) since 2009 and represents Sweden in the EU HTA Network (HTAN). Recently she acted as regional advisor to the WHO Egypt office and the WHO in the EMRO Region. She publishes frequently in scientific journals and acts as reviewer and associated editor in several journals, e.g. the International Journal of Technology Assessment in Health Care (IJTAHC).

Latin America Policy Forum Chair, Hector Castro (Colombia), 2020-2023

Hector Castro is a Doctor in Medicine and Surgery. He has an MSc in Health Policy, Planning and Financing, from the London School of Hygiene & Tropical Medicine (LSHTM) and a joint degree with the London School of Economics & Political Science (LSE). He specialized in Health Management and had a previous MSc in Occupational Health (Public Health Branch). He is a Doctor in Public Health and Policy/Health Economics from the University of London (LSHTM), and former Takemi Postdoctoral Fellow at the T.H. Chan Harvard School of Public Health.

Dr. Castro has over 18 years of broad professional experience, as Chief Officer, Technical Advisor, Director and Manager in strategic planning, quality assurance, health, safety and environment for pharmaceutical, health insurance and non-governmental organizations. His main focus of work has been on health systems` strengthening in areas such as quality assurance, assessment, strategic purchasing and provision of healthcare technologies (including medicines, devices and procedures).

Dr. Castro has more than ten years of experience as an international consultant in health care access, health economics, health policy, priority setting, health technology assessment (HTA) and health systems´ reform. He is also familiar with and has relevant experience in health systems and markets in low and middle-income countries (LMICs).  His previous working experience includes the US, United Kingdom, Colombia, Ecuador, Ukraine, Belarus, Thailand, Peru, Costa Rica, Brazil, Mexico, Chile, Turkey and Tunisia. He also has experience as a researcher and lecturer for undergraduate and post graduate students in ivy league institutions in Latin America, the US and United Kingdom.

Dr. Castro is a former funding Chief Executive Director of the HTA Institute of Colombia (IETS) and Director of Medicines and Technologies at the Ministry of Health and Social Protection of Colombia. Currently, he is Senior Technical Director of Pharmaceutical Economics and Financing at MSH. Starting June 2018 and until 2021, he will serve at the Board of Directors of the Health Technology Assessment International (HTAi), one of the most prominent international networks in the field of HTA.

Asia Policy Forum Chair, Brendon Kearney (Australia), 2018-2022

Professor Kearney presently works as a Clinical Professor in the Faculty of Medicine, University of Adelaide, practicing as a Consultant in the Haematology Unit of the Royal Adelaide Hospital (RAH) Cancer Service with a private practice based at the Royal Adelaide Hospital. He also has management responsibilities for pathology services at the RAH.

Professor Kearney has chaired numerous committees including the Health Policy Advisory Committee on Technology (HealthPACT) since 2003. For 10 years, he was the Deputy Chairman of the Medical Services Advisory Committee (MSAC), Australia’s Health Technology Assessment committee for the assessment and recommendations on procedures, devices and diagnostics. This involved the establishment of policies and systems for HTA assessment linked directly to reimbursement decisions. He has also served on the National Health and Medical Research Council for twelve years and has held various senior policy and management roles in the Australian Health System. He is a past-Chair and current Board member of EuroScan International and is a current Board member of HTAsiaLink.

Professor Kearney has been awarded the Sydney Sax medal for services to health and an Order of Australia for contribution to emergency services and health research.